Arrowhead Pharmaceuticals · 9 hours ago
Summer Intern, Bioassays
Arrowhead Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative drugs for genetic diseases. The Pharmacovigilance Systems Intern will support laboratory projects and gain hands-on experience in RNA isolation assays, data analysis, and scientific collaboration.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Develop an understanding of the scientific background and workflow for RNA isolation assays and related experimental approaches
Under supervision, establish and optimize assay parameters and conditions for isolating RNA from specific cellular compartments
Perform experimental readouts using multiple methods to confirm assay performance and results
Analyze experimental data and organize results using appropriate analytical tools
Maintain accurate and well-organized experimental records
Communicate findings and present results to the project team during meetings
Collaborate with scientists to support continued assay refinement and project progression
Qualification
Required
Currently enrolled student in an accredited university Master's degree program in Biology or a related field
Familiarity with RNA-related techniques
Hands-on experience with biological laboratory techniques
Strong verbal and written communication skills
Excellent problem-solving and analytical skills
Excellent verbal and written communication skills, including comfort presenting in group settings
Strong problem-solving and organizational skills
Proficiency in Microsoft Office applications
Preferred
Previous experience with RNA isolation techniques
Familiarity with Microsoft Excel and GraphPad Prism
Strong interest in RNA biology, assay development, or discovery research
Attention to detail and enthusiasm for learning new experimental approaches
Benefits
Competitive salaries
An excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Funding
Current Stage
Public CompanyTotal Funding
$2.45BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2026-01-07Post Ipo Equity· $200M
2026-01-07Post Ipo Debt· $625M
2024-11-26Post Ipo Equity· $325M
Leadership Team
Christopher Anzalone
President and Chief Executive Officer
Recent News
2026-01-08
Company data provided by crunchbase